Merck Gets CHMP Positive Opinion for V920 Ebola Zaire Virus Vaccine

Date : 10/18/2019 @ 11:37AM
Source : Dow Jones News
Stock : Merck and Co Inc (MRK)
Quote : 84.13  0.0 (0.00%) @ 10:14AM

Merck Gets CHMP Positive Opinion for V920 Ebola Zaire Virus Vaccine

Merck (NYSE:MRK)
Historical Stock Chart

2 Months : From Sep 2019 to Nov 2019

Click Here for more Merck Charts.

By Colin Kellaher


Merck & Co. (MRK) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of the V920 investigational vaccine for the Ebola Zaire virus.

The Kenilworth, N.J., drug maker said V920, if approved by the European Commission, would be authorized under the brand name Ervebo and indicated for active immunization of individuals 18 years of age or older.

The European Commission generally follows the CHMP's recommendations.

The U.S. Food and Drug Administration last month accepted and granted priority review to Merck's biologics license application for V920.


Write to Colin Kellaher at


(END) Dow Jones Newswires

October 18, 2019 07:22 ET (11:22 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest MRK Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.